Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment
Authors
Keywords
-
Journal
JNCI-Journal of the National Cancer Institute
Volume 109, Issue 4, Pages -
Publisher
Oxford University Press (OUP)
Online
2016-10-27
DOI
10.1093/jnci/djw261
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology
- (2016) Don S. Dizon et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
- (2015) Victoria Hillerdal et al. BIODRUGS
- Cross-Reactivity, Epitope Spreading, andDe NovoImmune Stimulation Are Possible Mechanisms of Cross-Protection of Nonvaccine Human Papillomavirus (HPV) Types in Recipients of HPV Therapeutic Vaccines
- (2015) Mayumi Nakagawa et al. Clinical and Vaccine Immunology
- Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
- (2015) D. GuhaThakurta et al. CLINICAL CANCER RESEARCH
- A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802
- (2015) Robert S. DiPaola et al. EUROPEAN UROLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer
- (2015) Sebastian Kreiter et al. NATURE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications
- (2014) JamesL Gulley et al. ASIAN JOURNAL OF ANDROLOGY
- Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
- (2014) Saar Gill et al. IMMUNOLOGICAL REVIEWS
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Humoral response to a viral glycan correlates with survival on PROSTVAC-VF
- (2014) C. T. Campbell et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T
- (2014) E J Small et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
- (2014) P. Kvistborg et al. Science Translational Medicine
- Adding fuel to the fire: Immunogenic intensification
- (2014) Geraldine O’Sullivan Coyne et al. Human Vaccines & Immunotherapeutics
- A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T
- (2014) D. G. McNeel et al. Cancer Immunology Research
- A Randomized Phase II Study of Immunization With Dendritic Cells Modified With Poxvectors Encoding CEA and MUC1 Compared With the Same Poxvectors Plus GM-CSF for Resected Metastatic Colorectal Cancer
- (2013) Michael A. Morse et al. ANNALS OF SURGERY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
- (2013) James W. Hodge et al. INTERNATIONAL JOURNAL OF CANCER
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
- (2013) Paul F. Schellhammer et al. UROLOGY
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Abscopal Regression of Antigen Disparate Tumors by Antigen Cascade After Systemic Tumor Vaccination in Combination with Local Tumor Radiation
- (2012) James W. Hodge et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
- (2012) Nadeem A. Sheikh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Unique Galectin Signature in Human Prostate Cancer Progression Suggests Galectin-1 as a Key Target for Treatment of Advanced Disease
- (2012) D. J. Laderach et al. CANCER RESEARCH
- CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma
- (2012) P. A. Prieto et al. CLINICAL CANCER RESEARCH
- Diversity of Antigen-Specific Responses Induced In Vivo with CTLA-4 Blockade in Prostate Cancer Patients
- (2012) S. S. Kwek et al. JOURNAL OF IMMUNOLOGY
- Therapeutic Cancer Vaccines: Current Status and Moving Forward
- (2012) J. Schlom JNCI-Journal of the National Cancer Institute
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Ravi A Madan et al. LANCET ONCOLOGY
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- Therapeutic vaccines
- (2012) James L. Gulley Human Vaccines & Immunotherapeutics
- Autoimmunity associated with immunotherapy of cancer
- (2011) S. M. Amos et al. BLOOD
- Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
- (2011) Véronique Corbière et al. CANCER RESEARCH
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients
- (2011) Nicola Hardwick et al. Immunotherapy
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
- (2011) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Role of ES Cell-Expressed Ras (ERas) in Tumorigenicity of Gastric Cancer
- (2010) Eiji Kubota et al. AMERICAN JOURNAL OF PATHOLOGY
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- A Viral Vaccine Encoding Prostate-Specific Antigen Induces Antigen Spreading to a Common Set of Self-Proteins in Prostate Cancer Patients
- (2010) N. J. Nesslinger et al. CLINICAL CANCER RESEARCH
- Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy
- (2010) W. D. Stein et al. CLINICAL CANCER RESEARCH
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression
- (2010) R. A. Madan et al. ONCOLOGIST
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
- (2009) James L. Gulley et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
- (2009) Mary L. Disis et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started